Biopharmaceutical company Telix Pharmaceuticals
(ASX:TLX) has extended its agreement with Endocyte, Inc.
The company has amended its contract with Endocyte in relation to providing prostate cancer imaging technology for their phase III trial.
This contract amendment further extends access to their kit and technical support to select European jurisdictions, and to the United States.
The Endocyte VISION trial is an international, prospective, open-label, multicentre, randomised phase III study for the treatment of patients with progressive prostate cancer.
Shares in Telix Pharmaceuticals
(ASX:TLX) closed 1.49 per cent higher to 68c yesterday
